Intravenous immunoglobulin in drug and device refractory patients with the symptoms of gastroparesis-an open-label study.
M AshatA LewisH LiaquatA StockerL McElmurrayV VedanarayananK SootaT HowellA KedarJ ObertThomas L AbellPublished in: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2017)
Although limited by the absence of placebo group, the data illustrate the role of autoimmunity and neuromuscular evaluation in patients with gastroparesis and support the utility of a diagnostic trial of immunotherapy in an effort to improve therapeutic outcomes for such patients.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- clinical trial
- prognostic factors
- randomized controlled trial
- peritoneal dialysis
- study protocol
- electronic health record
- emergency department
- machine learning
- metabolic syndrome
- depressive symptoms
- double blind
- low dose
- sleep quality
- skeletal muscle
- adverse drug
- placebo controlled